Overview

Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer

Status:
Active, not recruiting

Trial end date:
2025-05-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to confirm the high pathologic complete response rate after neoadjuvant chemotherapy with FEC followed by weekly paclitaxel and concurrent trastuzumab in Human Epidermal growth factor receptor2 (HER2) positive non operable breast cancer

Phase:

Phase 2

Details

Lead Sponsor:

Lucia Del Mastro,MD

Treatments:

Albumin-Bound Paclitaxel
Cyclophosphamide
Epirubicin
Fluorouracil
Paclitaxel
Trastuzumab